3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
7
Phase 2
5
Phase 1/2
3
Phase 3
2
Status
Active not recruiting
2
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
CNS
1
Conditions
Neurofibromatosis 1
1
Neurofibroma, Plexiform
1
Neoplasm Metastasis
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Carboplatin
106
Cisplatin
97
Paclitaxel
78
pembrolizumab
69
Gemcitabine
59
Pemetrexed
49
Cyclophosphamide
46
Docetaxel
45
Dexamethasone
45
durvalumab
44
Capecitabine
44
Radiotherapy
40
Nivolumab
37
Lenalidomide
37
Specimen Handling
36
Doxorubicin
36
Rituximab
34
Oxaliplatin
34
Bevacizumab
33
Magnetic Resonance Spectroscopy
32
Fluorouracil
32
atezolizumab
29
Etoposide
29
Vincristine
26
Radiation
26
Leucovorin
26
Letrozole
24
Bortezomib
24
Fulvestrant
23
Prednisone
22
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Active not recruiting
×
AZD 6244
×
Clear all
NCT04924608
2026-03-23
KOMET
AstraZeneca
Phase 3
Active not recruiting
145 enrolled
17 charts
1 FDA
NCT01933932
2025-11-19
SELECT-1
AstraZeneca
Phase 3
Active not recruiting
510 enrolled
16 charts